Milestone Scientific Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 revenue rose 22% year-over-year to $2.8M, driven by strong Medical segment growth and international Dental orders. Gross margin declined due to product mix and tariffs, but net loss narrowed. Guidance for 2026 was reaffirmed, with Q3 expected to be seasonally lower.
-
The meeting approved all proposals, including director elections, increased authorized shares, and expanded the equity incentive plan. Leadership emphasized operational discipline, growth, and alignment of executive incentives with performance milestones.
-
Revenue and gross profit remained stable, with significant cost reductions narrowing net loss by 58%. Medical segment revenue more than doubled, driven by CompuFlo adoption and digital marketing, while new financing supports growth and international expansion.
Fiscal Year 2025
-
Disciplined restructuring and targeted growth initiatives led to improved operating results in 2025, with double-digit revenue growth and significant CompuFlo expansion expected in 2026. Cash flow break even is targeted for early 2027.
-
Q3 2025 saw stable revenues and gross profit, with operating expenses reduced by over $500,000 year-over-year. Dental remains the main revenue driver, while medical segment progress hinges on Medicare reimbursement and focused commercialization. Cash position supports operations for several quarters.
-
Q2 2025 revenue rose 25% year-over-year to $2.3M, led by international dental sales, while operating loss narrowed. Medicare reimbursement progress and new leadership set the stage for focused growth in both dental and medical segments.
Fiscal Year 2024
-
Q3 2024 revenue grew 22% year-over-year to $2.5M, led by strong dental and medical segment advances, including Medicare reimbursement for CompuFlo and international expansion. Gross margins remained high, and net loss improved due to operational gains and a $2M tax asset sale.
-
Medicare reimbursement approval and a new distributor partnership have accelerated commercialization, with a focus on building recurring revenue in pain management clinics. The technology offers significant clinical and economic benefits, while the dental business remains profitable and international expansion is underway.
-
A high-margin, debt-free company leverages proprietary injection technology to expand from a profitable dental legacy into the $2 billion U.S. epidural market, supported by strong clinical validation, recent Medicare reimbursement wins, and strategic partnerships for disciplined commercial rollout.
-
Medicare reimbursement for CompuFlo and a new partnership with Axial Biologics mark a pivotal commercial milestone, while U.S. e-commerce dental sales and gross margins improved. Despite lower international sales, the company posted a Q2 net profit and maintains a strong balance sheet.